The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma.

"part of the single-cell expression data used in this study has been deposited in the european genome-phenome archive (ega) database under the accession code egas00001005019 and we are still in process of data deposition for the rest of the sequencing data. availability of data and materials all r scripts supporting the findings of this paper are available on github ( https://github com/lkmklsmn/b_cell_lymphoma/ )."

"availability of data and materials all r scripts supporting the findings of this paper are available on github ( https://github com/lkmklsmn/b_cell_lymphoma/ )."

"Declarations Ethics approval and consent to participateAll patient samples were collected after obtaining written informed consent and approval from the Institutional Review Board at The University of Texas MD Anderson Cancer Center. Consent for publicationNot applicable. Competing interestsMW is consultant to AstraZeneca, BeiGene, BioInvent, CSTone, Deciphera, DTRM Biopharma (Cayman) Limited, Epizyme, Genentech, InnoCare, Janssen, Juno Therapeutics, Kite Pharma, Lilly, Loxo Oncology, Miltenyi Biomedicine GmbH, Oncternal, Pepromene Bio, Pharmacyclics, VelosBio. MW has received research support from Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Genmab, Genentech, Innocare, Janssen, Juno Therapeutics, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics, VelosBio, Vincerx. MW received a speaker honoraria from Acerta Pharma, Anticancer Association, AstraZeneca, BeiGene, BGICS, BioInvent, CAHON, Clinical Care Options, Dava Oncology, Eastern Virginia Medical School, Epizyme, Hebei Cancer Prevention Federation, Imedex, Janssen, Kite Pharma, Leukemia & Lymphoma Society, LLC TS Oncology, Medscape, Meeting Minds Experts, Miltenyi Biomedicine GmbH, Moffit Cancer Center, Mumbai Hematology Group, OMI, OncLive, Pharmacyclics, Physicians Education Resources (PER), Practice Point Communications (PPC), The First Afflicted Hospital of Zhejiang University. ZZ is a consultant of Melax. Competing interests MW is consultant to AstraZeneca, BeiGene, BioInvent, CSTone, Deciphera, DTRM Biopharma (Cayman) Limited, Epizyme, Genentech, InnoCare, Janssen, Juno Therapeutics, Kite Pharma, Lilly, Loxo Oncology, Miltenyi Biomedicine GmbH, Oncternal, Pepromene Bio, Pharmacyclics, VelosBio. MW has received research support from Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Genmab, Genentech, Innocare, Janssen, Juno Therapeutics, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics, VelosBio, Vincerx. MW received a speaker honoraria from Acerta Pharma, Anticancer Association, AstraZeneca, BeiGene, BGICS, BioInvent, CAHON, Clinical Care Options, Dava Oncology, Eastern Virginia Medical School, Epizyme, Hebei Cancer Prevention Federation, Imedex, Janssen, Kite Pharma, Leukemia & Lymphoma Society, LLC TS Oncology, Medscape, Meeting Minds Experts, Miltenyi Biomedicine GmbH, Moffit Cancer Center, Mumbai Hematology Group, OMI, OncLive, Pharmacyclics, Physicians Education Resources (PER), Practice Point Communications (PPC), The First Afflicted Hospital of Zhejiang University. ZZ is a consultant of Melax."

"Funding This study was supported by the generous philanthropic support to the MD Anderson B-cell Lymphoma Moon Shot Project, philanthropy funds from The Gary Rogers Foundation, Kinder Foundation, and the Cullen Foundation, and start-up research funds kindly provided to M.W. by MD Anderson Cancer Center. This study was also supported by the NIH-funded Cancer Center Support Grant (CCSG) P30 CA016672 (Peter Pisters, Principal Investigator) and the NIH Core Grant for the Sequencing and Microarray Facility (CA016672). F.Y. is a CPRIT Predoctoral Fellow in the Biomedical Informatics, Genomics and Translational Cancer Research Training Program (BIG-TCR) funded by Cancer Prevention & Research Institute of Texas (CPRIT RP210045). Z.Z. was partially supported by an NIH grant (R01LM012806), a CPRIT grant (RP180734), and a University Chair Professorship fund. We thank the patients and their families who contributed to this research study. We thank Paul Dolber for his critical editing of the manuscript."